|Interferon/Lamivudine/Entecavir/Which one is for me?
Jan 8, 2002
Doctor, I was diagnosed about a year ago with HepB as a Chronic Carrier. My AST is 100 and ALT 226. My profile: HBsAg+, HBeAg+, HBcAB+ but HBsAB-. Liver bopsy indicates diffuse fattu infiltration.... Image obtained post demostrates no abnormality.
1)What results should I expect from a tratment? I understand we want to stop the damage occuring at my liver (high enzimes indicate damage to the liver and mine are high). 2) What does it mean to "get cured"? 3) In what percentage patients with my profile can get cured? 4) How can i find what is the best treatment for me? I don't want to be part of clinical trial if Interferon or Lamivudine would be the right option for me. 5) How can I approach my doctor (first visit) to get the answers and to make it clear I want his help to find the right treatment, and not just be one more number in a trial. I don't want to offend him, but also don't want to be a quiet lab rat. Thanks a lot.
| Response from Dr. Dieterich
Actually, your chances are probably better of a cure if you are in one of the new clinical trials of LDT in combo with 3TC. There is no pure placebo arm in that one, the worst you can get is 3TC. Entecavir also sounds promising as does the Achilion Drug ACH 443. There is no clear answer as to what the right treatment is. The right one is the one that works for you. Any of these new drugs are worth a try. Good luck! DTD
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.